Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, announced th...
As pharmaceutical manufacturers face increasing pressure to maintain production continuity, ensure regulatory compliance, and manage ageing equipment, the ...
The promise of precision oncology depends not only on scientific innovation but also on successful implementation in routine clinical practice. Drawing on ...
Strategic partnership integrates Pluristyx's clinical-grade iPSC platform into Made Scientific's CDMO services, giving developers a single-source path fr...
Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform&nbs...
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agon...
As oncology care becomes increasingly complex, traditional attribution models used in value-based care programs may no longer fully reflect how patients ar...
SGS, the world's leading testing, inspection and certification company, is pleased to announce that it has acquired CMIC, INC., a specialized provider of...
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are n...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, introd...
Zymo Research, a global leader in genomics tools, announced the launch of Zymo Services, a dedicated portfolio of end-to-end next-generation sequencing (...
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an ex...
© 2026 Biopharma Boardroom. All Rights Reserved.
